Researcher.Life Logo

Biochemical Pharmacology : Impact Factor & More

eISSN: 1873-2968pISSN: 0006-2952

Aims and Scope of Biochemical Pharmacology

Biochemical Pharmacology is a peer-reviewed medical journal published by Elsevier. It covers research on the pharmacodynamics and pharmacokinetics of drugs and non-therapeutic xenobiotics. The editor-in-chief is S. J. Enna, University of Kansas Medical Center, Kansas City. Less

Key Metrics

CiteScore
9.3
Eigenfactor
0.01 - 0.05
Impact Factor
5 - 10
Scite Index
0.94 5-Year SI
SJR
Q1Biochemistry
SNIP
1.25
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Biochemical Pharmacology

Biochemical Pharmacology Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher PERGAMON-ELSEVIER SCIENCE LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1958
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Biochemical Pharmacology ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Biochemical Pharmacology

Ranolazine exerts cardioprotection through attenuating mitochondrial dynamic imbalance in trastuzumab-induced cardiotoxicity in rats.
  • 1 Aug 2026
  • Biochemical pharmacology
NPTX2 accelerates cell cycle progression, activates EMT, and regulates glycolytic metabolic pathways to promote clear cell renal cell carcinoma progression.
  • 1 Aug 2026
  • Biochemical pharmacology
Fangchinoline derivative LYY-34 suppresses TNBC by inhibiting BLM DNA helicase from unfolding of c-MYC promoter G-quadruplex DNA.
  • 1 Aug 2026
  • Biochemical pharmacology
Retraction notice to "Omentin-1 attenuates salt-sensitive hypertension via GRK4/AT1R downregulation mediated by the ROS/c-Myc pathway" [Biochem. Pharmacol. 243 (2026) 117489
  • 1 Aug 2026
  • Biochemical pharmacology
Discovery of novel CSF1R inhibitor for triple-negative breast cancer (TNBC) treatment through TAMs reprogramming.
  • 1 Aug 2026
  • Biochemical pharmacology
Cannabinoids and the autophagy-related signaling in brain tumors: from mechanistic insights to therapeutic frontiers in glioblastoma.
  • 1 Aug 2026
  • Biochemical pharmacology
Ranolazine exerts cardioprotection through attenuating mitochondrial dynamic imbalance in trastuzumab-induced cardiotoxicity in rats.
  • 1 Aug 2026
  • Biochemical pharmacology
NPTX2 accelerates cell cycle progression, activates EMT, and regulates glycolytic metabolic pathways to promote clear cell renal cell carcinoma progression.
  • 1 Aug 2026
  • Biochemical pharmacology
Fangchinoline derivative LYY-34 suppresses TNBC by inhibiting BLM DNA helicase from unfolding of c-MYC promoter G-quadruplex DNA.
  • 1 Aug 2026
  • Biochemical pharmacology
Retraction notice to "Omentin-1 attenuates salt-sensitive hypertension via GRK4/AT1R downregulation mediated by the ROS/c-Myc pathway" [Biochem. Pharmacol. 243 (2026) 117489
  • 1 Aug 2026
  • Biochemical pharmacology
Discovery of novel CSF1R inhibitor for triple-negative breast cancer (TNBC) treatment through TAMs reprogramming.
  • 1 Aug 2026
  • Biochemical pharmacology
Cannabinoids and the autophagy-related signaling in brain tumors: from mechanistic insights to therapeutic frontiers in glioblastoma.
  • 1 Aug 2026
  • Biochemical pharmacology

FAQs on Biochemical Pharmacology